$6.41 Billion is the total value of Avoro Capital Advisors LLC's 46 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 100.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
ASND | Buy | ASCENDIS PHARMAsponsored adr | $343,658,800 | +7.5% | 3,670,000 | +2.5% | 5.36% | +23.6% |
KRYS | Buy | KRYSTAL BIOTECH INC | $297,604,380 | -1.0% | 2,565,555 | +0.2% | 4.64% | +13.8% |
MRTX | Buy | MIRATI THERAPEUTICS INC | $290,399,971 | +44.7% | 6,666,666 | +20.0% | 4.53% | +66.4% |
MDGL | Buy | MADRIGAL PHARMACEUTICALS INC | $227,092,200 | -35.1% | 1,555,000 | +2.6% | 3.54% | -25.4% |
Buy | MOONLAKE IMMUNOTHERAPEUTICSclass a ord | $113,999,943 | +29.6% | 1,999,999 | +15.9% | 1.78% | +49.0% | |
RARE | Buy | ULTRAGENYX PHARMACEUTICAL INC | $53,475,000 | +54.6% | 1,500,000 | +100.0% | 0.83% | +77.8% |
New | STRUCTURE THERAPEUTICS INCsponsored adr | $50,420,000 | – | 1,000,000 | +100.0% | 0.79% | – | |
AKRO | New | AKERO THERAPEUTICS ORD | $28,099,972 | – | 555,555 | +100.0% | 0.44% | – |
RCKT | New | ROCKET PHARMACEUTICALS INC | $25,612,500 | – | 1,250,000 | +100.0% | 0.40% | – |
Buy | TANGO THERAPEUTICS INC | $25,022,220 | +359.6% | 2,222,222 | +35.5% | 0.39% | +427.0% | |
CERE | New | CEREVEL THERAPEUTICS HLDNG | $20,859,766 | – | 955,555 | +100.0% | 0.32% | – |
ARWR | Buy | ARROWHEAD PHARMACEUTICALS INC | $15,181,550 | +19.1% | 565,000 | +58.1% | 0.24% | +37.0% |
TSHA | New | TAYSHA GENE THERAPIES INC | $12,403,000 | – | 3,925,000 | +100.0% | 0.19% | – |
MRUS | New | MERUS N V | $10,479,990 | – | 444,444 | +100.0% | 0.16% | – |
QQQ | New | Invesco QQQ Trustput | $1,220,000 | – | 500,000 | +100.0% | 0.02% | – |
New | AEGLEA BIOTHERAPEUTICS INC | $140,361 | – | 11,458 | +100.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
AMICUS THERAPEUTICS INC | 36 | Q3 2023 | 17.9% |
MIRATI THERAPEUTICS INC. | 35 | Q3 2023 | 17.2% |
BIOMARIN PHARMACEUTICAL INC | 31 | Q3 2023 | 8.0% |
SAREPTA THERAPUTICS INC | 28 | Q3 2023 | 14.8% |
ASCENDIS PHARMA | 28 | Q3 2023 | 9.1% |
ARGENX SE | 26 | Q3 2023 | 9.5% |
IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
FENNEC PHARMACEUTICALS INC | 25 | Q3 2023 | 0.4% |
MADRIGAL PHARMACEUTICALS INC | 22 | Q3 2023 | 7.2% |
XENON PHARMACEUTICALS INC | 22 | Q3 2023 | 3.3% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
DICE Therapeutics, Inc. | February 14, 2023 | 2,525,555 | 5.3% |
IOVANCE BIOTHERAPEUTICS, INC. | February 14, 2023 | 7,020,000 | 4.4% |
IVERIC bio, Inc. | February 14, 2023 | 6,750,000 | 5.0% |
Kura Oncology, Inc. | February 14, 2023 | 3,105,000 | 4.5% |
Aadi Bioscience, Inc. | September 26, 2022 | 2,849,402 | 11.7% |
ARENA PHARMACEUTICALS INC | February 11, 2022 | 1,235,000 | 2.0% |
AVADEL PHARMACEUTICALS PLC | February 11, 2022 | 1,670,000 | 2.9% |
FENNEC PHARMACEUTICALS INC. | February 11, 2022 | 1,200,000 | 4.6% |
POINT Biopharma Global Inc.Sold out | February 11, 2022 | 0 | 0.0% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
SC 13G/A | 2024-04-23 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.